Emergent BioSolutions SVP logs tax disposition, option grant

Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported two equity compensation transactions.

Rhea-AI Filing Summary

Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported two equity compensation transactions. On March 5, 2026, 9,397 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, leaving him with 66,681 common shares directly held.

On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of $0.00 per share, increasing his directly held options to 254,948. The options vest in three equal installments beginning on the day prior to the anniversary date of the grant.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Williams Paul Anthony

Role SVP, Products Business

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	9,397	$8.44	$79K
Grant/Award	Employee Stock Option (Right to buy)	44,834	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to buy) — 254,948 contracts (Direct); Common Stock — 66,681 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
2. F2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Emergent BioSolutions (EBS) report for Paul Anthony Williams?

Emergent BioSolutions reported that SVP Paul Anthony Williams disposed of 9,397 common shares for tax withholding and received a grant of 44,834 employee stock options. These transactions reflect routine equity compensation activity rather than open-market buying or selling of stock.

Was the share disposal by Emergent BioSolutions SVP Paul Anthony Williams an open-market sale?

No, the 9,397-share disposal was for tax withholding tied to restricted stock unit vesting, not an open-market sale. Shares were withheld at a value of $8.44 per share to satisfy tax obligations triggered by the RSU settlement.

How many Emergent BioSolutions shares does Paul Anthony Williams hold after these transactions?

After the reported tax-withholding transaction, Paul Anthony Williams directly holds 66,681 shares of Emergent BioSolutions common stock. In addition, his directly held employee stock options total 254,948 shares following the new option grant recorded in the filing.

What are the details of the stock option grant to Emergent BioSolutions executive Paul Anthony Williams?

Paul Anthony Williams received an employee stock option grant for 44,834 shares with an exercise price of $0.00 per share. The options vest in three equal installments, beginning on the day prior to each anniversary of the grant date, according to the disclosure.

How do the reported Form 4 transactions affect Paul Anthony Williams’ ownership in Emergent BioSolutions (EBS)?

His directly held common shares decreased by 9,397 due to tax withholding, leaving 66,681 shares. At the same time, his derivative holdings increased, as the 44,834-share stock option grant brought his total directly held options to 254,948, expanding his potential future equity exposure.

Why were Emergent BioSolutions shares withheld from Paul Anthony Williams on March 5, 2026?

Shares were withheld to pay taxes arising from the vesting and settlement of restricted stock units. Specifically, 9,397 shares of common stock were surrendered at $8.44 per share to cover the associated tax liability instead of making a separate cash payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 09:08 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Paul Anthony

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Products Business

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		F		9,397(1)	D	$8.44	66,681	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$8.99	03/03/2026		A		44,834		(2)	03/02/2033	Common Stock	44,834	$0	254,948	D

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.